• On 12 June 2026, Pulse Biosciences, Inc. was added to the S&P Healthcare Equipment Select Industry Index, boosting its visibility among healthcare equipment peers and index-linked investors.
• This index inclusion comes as the company reports a strong financial health score within its industry and a recent rise in institutional ownership, despite limited disclosed operating data.
• We’ll now explore how the company’s addition to the S&P Healthcare Equipment Select Industry Index may influence Pulse Biosciences’ investment narrative.

Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Pulse Biosciences Investment Narrative Recap

To own Pulse Biosciences, you have to believe its nanosecond pulse field ablation platform can convert early cardiac and thyroid data into meaningful commercial adoption despite ongoing losses. The S&P Healthcare Equipment Select Industry Index inclusion improves visibility, but it does not materially change the near term catalyst of advancing nPulse cardiac catheter trials or the key risk of high cash use against minimal revenue.

The most relevant recent update is the strong financial health score of 75 out of 203 in its industry, alongside a 30% quarter over quarter rise in institutional ownership. Together with index inclusion, this stronger balance sheet profile may support confidence in Pulse Biosciences’ ability to fund pivotal studies like NANOPULSE AF, a key driver for whether early procedure success can translate into broader adoption.

Yet behind the promising index news, investors should be aware that persistent high operating costs against very limited revenue could still...

Pulse Biosciences' narrative projects $29.7 million revenue and $3.9 million earnings by 2028. This requires 601.5% yearly revenue growth and a $78.6 million earnings increase from -$74.7 million today.

Uncover how Pulse Biosciences' forecasts yield a $22.00 fair value, a 14% downside to its current price.

Exploring Other Perspectives

Some analysts were assuming revenue could grow nearly 690% a year to about US$42.3 million, which is far more optimistic than consensus forecasts and may look different now that index inclusion and institutional shifts highlight how uncertain early Vybrance and nPulse catheter adoption really is.

Explore another fair value estimate on Pulse Biosciences - why the stock might be worth 14% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pulse Biosciences research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Pulse Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pulse Biosciences' overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.